Promacta (eltrombopag): Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease
Audience: Hematology healthcare professionals GlaxoSmithKline and FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated with eltrombopag, a thrombopoietin receptor…
No related posts.




facebook
rss
twitter